Kevin’s career also includes several years of corporate finance and manufacturing experience with SG Cowen’s Health Care Investment Banking Group and with SyStemix, a stem-cell therapy company acquired by Novartis. ZS Pharma General Information Description. We are currently focused on using our proprietary ion-trap technology to develop new treatments. Clinical News. The company was founded by Alvaro F. Guillem and Donald J The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition The company is focused on the development and commercialization of highly selective, non-systemically absorbed therapeutics to treat renal, cardiovascular, liver and metabolic diseases. Before ZS Pharma, he held commercial leadership roles at Exelixis and Genentech, where he launched multiple new products and line extensions in oncology and hematology. Two new software products—VERSO Field Insights and VERSO Brand Insights—join ZS's existing Orchestration Engine in the new VERSO product family. We are focused on the development and commercialization of FDA issues second CRL for AZ's hyperkalemia candidate...other ions throughout the GI tract. This business is unclaimed. It develops treatment of hyperkalemia. ZS Pharma was founded in 2008, became a public company in 2014 and, in December 2015, joined the AstraZeneca Group. Market leader in innovative products. The Registered Agent on file for this company is CT Corporation System and is located at 1999 Bryan St. Suite 900, Dallas, TX 75201-3136. BioCentury | Mar 22, 2017. The company's filing status is listed as In Existence and its File Number is 0801135060. Find 90 listings related to Zs Pharmaceutical in Denver on YP.com. We are a biopharmaceutical company dedicated to challenging the status quo in disease areas where therapeutic options have been limited. Trademarks may include brand names, product names, logos and slogans. This page shows the latest ZS Pharma news and features for those working in and with pharma, biotech and healthcare. The US firm uses its ion­-trap technology to develop new treatments for hyperkalaemia, a serious condition of high potassium levels in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF). ZS Pharma develops and commercialises highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic disorders. Owners who claim their business can update listing details, add photos, respond to reviews, and more. Astrazeneca, UK's second-largest drugmaker, agreed to buy ZS Pharma for $2.7 billion in cash, sweeping it from Swiss rival Actelion. The company's principal address is 508 Wrangler Drive Suite 100, Coppell, TX 75019. ZS Pharma was founded in 2008, became a public company in 2014 and, in December 2015, joined the AstraZeneca Group. Together, the three products accounted for almost 40 per cent of revenues in 2014. That portfolio will, if the deal is completed, include ZS Pharma’s first product candidate, which is now under U.S. regulatory review—the potassium-binding compound ZS-9 for hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. AstraZeneca is a company with a turbulent history but, for now, a promising future. AstraZeneca last year swooped on ZS Pharma of the US for $2.7bn in an effort to boost its pipeline of products and reassure investors concerned about its patent cliff. AZ gained ZS-9 through its $2.7 billion acquisition of ZS Pharma Inc.... Read More. Buying California-based ZS Pharma for $2.7bn gives AstraZeneca PLC a potential blockbuster already by next year, adds substance to the pure pharma's offerings for cardiovascular and metabolic disease, and should support its return to growth strategy, analysts say. About ZS Pharma . ZS Pharma is a biopharmaceutical company with offices in Coppell, Texas, and San Mateo, California. Zs Pharma, Inc. is a Texas Foreign For-Profit Corporation filed On June 15, 2009. ZS Pharma is a biopharmaceutical company with offices in Coppell, Texas, and San Mateo, California. ZS Pharma was founded in 2008, became a public company in 2014 and, in December 2015, joined the AstraZeneca Group. ZS Pharma's lead therapeutic candidate, ZS-9, is an investigational treatment for hyperkalemia that is being evaluated in late-stage clinical trials to demonstrate its ability to safely and effectively remove excess potassium from the blood and maintain normal potassium levels. About ZS Pharma ZS Pharma, founded in 2008, is a publicly traded biopharmaceutical company dedicated to challenging the status quo in disease states where therapeutic options have been limited. Relypsa has been seen as a major M&A target after AstraZeneca’s acquisition of ZS Pharma last year, with a number of Big Pharma names (including Actelion, which failed at … Trademark applications show the products and services that ZS Pharma is developing and marketing. BioCentury | Mar 17, 2017. UNCLAIMED . She has also worked with U.S. Customs on classification and clearance of products coming into the U.S. Norma has held various positions with companies in many medical areas, including Abbott Diagnostics Division of Abbott Laboratories; Alcon Laboratories, a Subsidiary of Novartis; and ZS Pharma, an Affiliate of AstraZeneca. AstraZeneca plc (LSE:AZN; NYSE:AZN) acquired ZS Pharma... Read More. AstraZeneca plc (/ ˌ æ s t r ə ˈ z ɛ n ə k ə /) is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its headquarters in Cambridge, England. ZS Pharma became a subsidiary of AstraZeneca in 2015 through a $2.7bn deal that saw the Anglo-Swedish Big Pharma firm add late-stage potassium-binding compound ZS-9 (sodium zirconium cyclosilicate) as a potential treatment for hyperkalaemia, a condition associated with chronic kidney disease (CKD).. At AstraZeneca, Luke has helped strengthen the company’s product portfolio, launching Tagrisso in the US, improving growth of the cardiovascular and metabolic portfolios, notably Brilinta, and through business development with investments in companies such as Acerta Pharma and the acquisition of ZS Pharma. Operator of a biopharmaceutical company. The ZS Pharma team combines deep … ZS PHARMA, INC. (ZSPH) financial statements (2021 and earlier) Company profile The company has been focused on using its proprietary ion-trap technology to develop new treatments of kidney and liver diseases that are focused on addressing unmet needs in the medical … Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, respiratory and inflammation. AstraZeneca has agreed to buy ZS Pharma, the US biotech company, for $2.7bn (£1.8bn) in cash, thwarting the ambitions of a Swiss rival in the deal-hungry pharmaceutical sector. ZS Pharma is a publicly-traded, specialty pharmaceutical company based in Coppell, Texas. See reviews, photos, directions, phone numbers and more for Zs Pharmaceutical locations in Denver, CO. Britain's AstraZeneca said on Friday it had agreed to buy U.S biotech company ZS Pharma for $2.7 billion, pipping Swiss firm Actelion to the prize in … ZS Pharma was founded in 2008, became a public company in 2014 and, in December 2015, joined the AstraZeneca Group. U.S. Coppell, TX Pharmaceuticals Pharmaceutical Preparations Pharmaceutical Preparations . The candidate, tipped to be a blockbuster product for AstraZeneca, has experienced … ZS-9 regulatory update...other ions throughout the GI tract. We combine oncology analytics, consulting, technology and design capabilities to generate actionable insights and solutions that drive real-world progress. ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. Trademark Date; NOMIKEL Pharmaceutical preparations … Prior to that, Mr. Asbury held a variety of positions at Genentech, most recently as Associate General Counsel and Senior Director of Transactional Law. Claim … 29 talking about this. ZS Pharma doesn't have any recent trademark applications, indicating ZS Pharma is focusing on its existing business rather than expanding into new products and markets. Company News. Business Services | Food & Beverage | Consumer Products & Services | Health | Tech & Communications | Industrial. NICE says no to AZ and Vifor’s rival hyperkalaemia drugs AZ acquired Lokelma ( sodium zirconium cyclosilicate) via a $2.7bn acquisition of ZS Pharma three years ago, but suffered serious setbacks in its approval thanks to manufacturing compliance issues. Zs Pharma, Inc . We are Distributors/Importers of Veterinary Medicines. Prior to ZS Pharma, he was the Vice President and General Counsel of Pharmacyclics where he helped the company negotiate a $975 million deal with Johnson & Johnson for ibrutinib, its Phase 2 molecule.
Schrozberg Wohnung Mieten, Pressemitteilungen Hessen Heute, Canada Covid Vaccine Delivery Schedule, Firmung Im Kölner Dom 2020, Golden Tulip Reviews, Starbound Sale History, Frankfurt Nach Mykonos Direktflug, Hazard Real Madrid, Arusha Meaning In Tamil, Der Weite Weg Der Hoffnung, Suits Staffel 6 Besetzung,